Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a leading ... to present at the Jefferies 3rd Annual Healthcare Conference in New ... 2009. , , The presentations will be available to ... accessed by visiting http://investors.gentiva.com/events.cfm . Visitors ...
... ... New hope for a much needed new approach for tackling Alzheimer,s disease ... in Philadelphia. At the inaugural Targeting Alzheimer,s with Novel Therapeutics conference, ... Edward Tobinick MD, Director of the Institute for Neurological Research, a private ...
... Men Fly off the Shelves for Father,s Day , , ... for chronic lower back pain may lie in a $59.99 biomechanically-engineered ... be the turning point for the sixty million adults who reported ... shoe many claim to be a medical breakthrough is now available ...
... Inc. a technology and services company focused on global eClinical solutions ... 45th DIA Annual Meeting to be held later this month in ... well as a number of exciting new features and functionality in ... , Reaffirming our ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
... Over Half a Million Varicose Vein Patients Treated with VNUS Closure ... VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide ... venous reflux disease , the underlying cause of ... week, it estimates the number of patients treated with the VNUS ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 2Health News:New Immune Approach for Treatment of Alzheimer's Disease 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 4Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 3Health News:DATATRAK Announces New Products and Features at DIA San Diego 4Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:A Milestone of Opportunity for VNUS Medical Technologies 2Health News:A Milestone of Opportunity for VNUS Medical Technologies 3
Bravo Vacuum Pump. Complete with tubing....
Stand with buffer tubes for calibration of Bravo pH capsule....
... lower esophhageal sphincter (LES) can ... a separate manometry system. pH ... identification accessory kit and Digitrapper ... locate the LES. The kit ...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
Medicine Products: